Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICS-II preoperative therapy trial in resectable gastric cancer
NL-OMON53113Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, oxaliplatin, capecitabine, paclitaxel and carboplatin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Event-free survival at 1 year after randomisation. Started Dec 2017; status: recruiting.
02
Drugs
docetaxeloxaliplatincapecitabinepaclitaxelcarboplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON53113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53113.